EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025

GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024.

Participants can access the conference call live via , and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the page of Emergent’s website.

Additional Investor Event – Webcast Information

Emergent will also provide a brief presentation and remarks during J.P. Morgan’s 2025 Leveraged Finance Conference. Participants may access the presentation via at 11:00 am eastern time on Monday, February 24, 2025.

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our  and follow us on , , ,  and .

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

  

Media Contact:

Assal Hellmer

Vice President, Communications



EN
18/02/2025

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financ...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWI...

March 3, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Fina...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025 GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024. Participants can access the conference call live via , and also by visiting the page of Emergent’s website. To participa...

February 18, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Aware...

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over year The ‘Lay, Spray, Stay’ opioid overdose educational video featuring Smith and how to use NARCAN® Nasal Spray will appear on local taxi television screens throughout the city Hundreds of NARCAN® Nasal Spray cartons will be given away to people in New Orleans t...

February 7, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As C...

January 16, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (...

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in needFocus remains on increasing access, raising awareness and ensuring strong supply to meet the ongoing demand of naloxone nasal spray GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. ...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch